GLP1R and type 2 diabetes mellitus: Biobank studies covering Boston (MGBB), New York (BioMe), Los Angeles (UCLA-ATLAS) and Helsinki (HUS) had overall lower rates of T2D individuals compared with the other studies and lower weights at baseline, which, together with the availability of more updated electronic health records (EHR) data, suggest a larger number of individuals being prescribed GLP1-RA for weight loss.